Common use of CONFIDENTIAL TREATMENT REQUESTED Clause in Contracts

CONFIDENTIAL TREATMENT REQUESTED. Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 1.168 Takeda Patents Licensed [***] Patent Patent / Publication Priority / Application Inventor(s) / Assignee(s) Title / Claims Status [***] [***] [***] [***] [***] CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 1.188 Ultragenyx Patents Ultragenyx [***] Patents [***] Ultragenyx [***] Patents [***] [3 pages omitted] CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 1.195 [***] CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 6.1 Listed Compounds [***] CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 6.3(a) [***] Research Plan [***] CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 6.10(b) [***] [4 pages omitted]

CONFIDENTIAL TREATMENT REQUESTED. Certain information in portions of this document have been omitted pursuant to a request for confidential treatment and, where applicable, have been marked with an asterisk (“[*****]”) to denote where omissions have been made. The confidential material has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to omitted portions marked “***”OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY SUCH SUIT, ACTION OR PROCEEDING AND, SOLELY FOR THE PURPOSES OF ENFORCING THIS AGREEMENT, OWNER AND MANAGER EACH IRREVOCABLY SUBMITS TO THE JURISDICTION OF ANY SUCH COURT IN ANY SUCH SUIT, ACTION OR PROCEEDING. Exhibit 1.168 Takeda Patents Licensed [***] Patent Patent / Publication Priority / Application Inventor(s) / Assignee(s) Title / Claims Status [***] [***] [***] [***] [***] CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been omitted and filed separately with the Securities and Exchange CommissionMANAGER APPOINTS AND DESIGNATES ICAHN ASSOCIATES LLC, HAVING AN ADDRESS AT 000 XXXXX XXXXXX, XXX XXXX, XXX XXXX 00000, ATTENTION: LEGAL DEPARTMENT, AS ITS TRUE AND LAWFUL ATTORNEY-IN-FACT AND DULY AUTHORIZED AGENT FOR THE LIMITED PURPOSE OF ACCEPTING SERVICING OF LEGAL PROCESS, AND MANAGER AGREES THAT SERVICE OF PROCESS UPON SUCH PARTY SHALL CONSTITUTE PERSONAL SERVICE OF SUCH PROCESS ON SUCH PERSON. Confidential treatment has been requested with respect to omitted portions marked “***”OWNER APPOINTS AND DESIGNATES CT CORPORATION, HAVING AN ADDRESS AT 000 XXXXXX XXXXXX, 00XX XXXXX, XXX XXXX, XXX XXXX 00000, AS ITS TRUE AND LAWFUL ATTORNEY-IN-FACT AND DULY AUTHORIZED AGENT FOR THE LIMITED PURPOSE OF ACCEPTING SERVICING OF LEGAL PROCESS, AND OWNER AGREES THAT SERVICE OF PROCESS UPON SUCH PARTY SHALL CONSTITUTE PERSONAL SERVICE OF SUCH PROCESS ON SUCH PERSON. Exhibit 1.188 Ultragenyx Patents Ultragenyx [***] Patents [***] Ultragenyx [***] Patents [***] [3 pages omitted] CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 1.195 [***] CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 6.1 Listed Compounds [***] CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 6.3(a) [***] Research Plan [***] CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 6.10(b) [***] [4 pages omitted]IF SUCH AGENT SHALL CEASE TO SO ACT, OWNER OR MANAGER, AS THE CASE MAY BE, SHALL IMMEDIATELY DESIGNATE AND APPOINT ANOTHER SUCH AGENT SATISFACTORY TO THE OTHER PARTY HERETO AND SHALL PROMPTLY DELIVER TO THE OTHER PARTY HERETO EVIDENCE IN WRITING OF SUCH OTHER AGENT’S ACCEPTANCE OF SUCH APPOINTMENT.

CONFIDENTIAL TREATMENT REQUESTED. Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 1.168 Takeda Patents Licensed [***] Patent Patent / Publication Priority / Application Inventor(s) / Assignee(s) Title / Claims Status [***] [***] [***] [***] [***] THE REGISTRANT HAS REQUESTED CONFIDENTIAL TREATMENT FOR CERTAIN PORTIONS OF THIS AGREEMENT. THOSE PORTIONS HAVE BEEN OMITTED FROM THIS COPY OF THE AGREEMENT AT THE PLACES INDICATED BY (XXXX); AND HAVE BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION XXXXXX Confidential Treatment Requested THE REGISTRANT HAS REQUESTED Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 1.188 Ultragenyx Patents Ultragenyx [***] Patents [***] Ultragenyx [***] Patents [***] [3 pages omitted] CONFIDENTIAL TREATMENT FOR CERTAIN PORTIONS OF THIS AGREEMENT. THOSE PORTIONS HAVE BEEN OMITTED FROM THIS COPY OF THE AGREEMENT AT THE PLACES INDICATED BY (XXXX); AND HAVE BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION XXXXXX Confidential Treatment Requested THE REGISTRANT HAS REQUESTED Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 1.195 [***] CONFIDENTIAL TREATMENT FOR CERTAIN PORTIONS OF THIS AGREEMENT. THOSE PORTIONS HAVE BEEN OMITTED FROM THIS COPY OF THE AGREEMENT AT THE PLACES INDICATED BY (XXXX); AND HAVE BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION XXXXXX Confidential Treatment Requested THE REGISTRANT HAS REQUESTED Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 6.1 Listed Compounds [***] CONFIDENTIAL TREATMENT FOR CERTAIN PORTIONS OF THIS AGREEMENT. THOSE PORTIONS HAVE BEEN OMITTED FROM THIS COPY OF THE AGREEMENT AT THE PLACES INDICATED BY (XXXX); AND HAVE BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION XXXXXX /s/ MPR - JCS /s/ VBL ---- ---- JCS VBL Confidential Treatment Requested THE REGISTRANT HAS REQUESTED Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 6.3(a) [***] Research Plan [***] CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been omitted and filed separately with the Securities and Exchange CommissionFOR CERTAIN PORTIONS OF THIS AGREEMENT. Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 6.10(b) [***] [4 pages omitted]THOSE PORTIONS HAVE BEEN OMITTED FROM THIS COPY OF THE AGREEMENT AT THE PLACES INDICATED BY (XXXX); AND HAVE BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION XXXXXX /s/ MPR - JCS /s/ VBL ---- ---- JCS VBL

CONFIDENTIAL TREATMENT REQUESTED. Exhibit 2.1.4 Assigned Contracts License Agreement between Seller and [*] dated January 22, 2004, as amended June 1, 2006. * Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions marked “***”portions. EXECUTION VERSION Exhibit 1.168 Takeda Patents Licensed [***] Patent Patent / Publication Priority / Application Inventor(s) / Assignee(s) Title / Claims Status [***] [***] [***] [***] [***] 2.6 Purchase Price Allocation Schedule EXECUTION VERSION CONFIDENTIAL TREATMENT REQUESTED Certain information Exhibit 7.1.6 Opinion of Counsel for Seller Bausch & Lomb Incorporated Onx Xxxxxx & Xxxx Xxxxx Xxxxxxxxx, XX 00000 Ladies and Gentlemen: We have acted as counsel for Alimera Sciences, Inc., a Delaware corporation (the “Company”), in connection with Asset Purchase Agreement, dated as of February 16, 2007 (the “Agreement”) by and between the Company and Bausch & Lomb Incorporated, a New York corporation (“Buyer”). This opinion is being rendered to you pursuant to Section 7.1.6 of the Agreement. Capitalized terms not otherwise defined in this document opinion have the meaning given them in the Agreement. In connection with the opinions expressed herein, we have made such examination of matters of law and of fact as we considered appropriate or advisable for purposes hereof. As to matters of fact material to the opinions expressed herein, we have relied upon the representations and warranties as to factual matters contained in and made by the Company pursuant to the Agreement, a certificate of an officer of the Company (the “Opinion Certificate”; a copy of which has been omitted provided to Buyer) and filed separately other certificates and statements of government officials. We have also examined originals or copies of such corporate documents or records of the Company as we have considered appropriate for the opinions expressed herein. We have assumed for the purposes of this opinion that the signatures on documents and instruments examined by us are authentic, that each document is what it purports to be, and that all documents submitted to us as copies or facsimiles conform with the Securities and Exchange Commissionoriginals, which facts we have not independently verified. Confidential treatment has been requested We have not conducted a docket search in any jurisdiction with respect to omitted portions marked litigation that may be pending against the Company or any of its officers or directors or undertaken any further inquiry other than as stated herein. In addition, we have reviewed the Company’s Amended and Restated Certificate of Incorporation and Bylaws, each as amended and in effect on the date hereof (the “***Charter Documents”. Exhibit 1.188 Ultragenyx Patents Ultragenyx [***] Patents [***] Ultragenyx [***] Patents [***] [3 pages omitted] CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been omitted ) and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 1.195 [***] CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 6.1 Listed Compounds [***] CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 6.3(a) [***] Research Plan [***] CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 6.10(b) [***] [4 pages omitted]following documents:

CONFIDENTIAL TREATMENT REQUESTED. Certain information in The undersigned, intending to be legally bound hereby, agree that this document has been omitted Schedule 2.8(i) shall be incorporated in, become part of and filed separately with be governed by the Securities [Amended and Exchange Commission. Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 1.168 Takeda Patents Licensed Restated] Carrier Access Agreement between New York Telecom Partners, LLC and [**]dated 12/21/99, as amended. NEW YORK TELECOM PARTNERS, LLC. By: /s/ Rxxxxxx X. XxXxxxxxxx Rxxxxxx X. XxXxxxxxxx, President Date: July 17, 2002 [*] Patent Patent / Publication Priority / Application Inventor(s) / Assignee(s) Title / Claims Status [***] [***] [***] [***] [***] * CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 1.188 Ultragenyx Patents Ultragenyx [***] Patents [***] Ultragenyx [***] Patents [***] [3 pages omitted] * CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 1.195 [***] * CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 6.1 Listed Compounds [***] * CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 6.3(a) [***] Research Plan [***] CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 6.10(b) [***] [4 pages omitted]WITH RESPECT TO THE OMITTED PORTIONS.

CONFIDENTIAL TREATMENT REQUESTED. Certain information Exhibit A Patent Rights as of the Effective Date The subject matter that pertains to the First Antibody in this document has been the claims (but not, for example, subject matter that would apply to a different antibody even if contained in the same claim) of the following patent applications: Patent Application No. Filing Date [***, 1 page] Portions of the exhibit, indicated by the xxxx “[***],” were omitted and have been filed separately with the Securities and Exchange CommissionCommission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with respect to omitted portions marked “***”. CONFIDENTIAL TREATMENT REQUESTED Exhibit 1.168 Takeda Patents Licensed B First Antibody Description [***, 1 page] Patent Patent / Publication Priority / Application Inventor(s) / Assignee(s) Title / Claims Status Portions of the exhibit, indicated by the xxxx “[***] [***] [***] [***] [***] CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been ],” were omitted and have been filed separately with the Securities and Exchange CommissionCommission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested CONFIDENTIAL TREATMENT REQUESTED Exhibit C Subsequent Antibody Descriptions [to be completed with respect to omitted portions marked the Definitive Agreement] Portions of the exhibit, indicated by the xxxx “***”. Exhibit 1.188 Ultragenyx Patents Ultragenyx [***] Patents [***] Ultragenyx [***] Patents [***] [3 pages omitted] CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been ],” were omitted and have been filed separately with the Securities and Exchange CommissionCommission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential treatment CONFIDENTIAL TREATMENT REQUESTED Exhibit D Pieris and Enumeral Form 8-K Filings Pieris Form 8-K Disclosure: On April 18, 2016, Pieris Pharmaceuticals, Inc. (the “Company”) and Pieris Pharmaceuticals GmbH, a wholly-owned subsidiary of the Company (together with the Company, “Pieris”), entered into a license and transfer agreement (the “Agreement”) with Enumeral Biomedical Holdings, Inc. (“Enumeral”), pursuant to which Pieris acquired a non-exclusive (except in the exclusive field described below) worldwide license to use specified patent rights and know-how owned by Enumeral to research, develop and market fusion proteins consisting of PD-1 antibodies linked to one or more Anticalin proteins for use in the oncology area. Enumeral also agreed not to practice or assist third parties in practicing in the exclusive field, consisting of licensed antibodies fused to Anticalin proteins in the oncology area. Under the Agreement, Pieris agreed to pay Enumeral an upfront license fee of $250,000 and, on May 31, 2016, a $750,000 maintenance fee. Under the initial license, Pieris also agreed to pay to Enumeral development milestones of up to an aggregate of $37.8 million for all products and indications and sales milestones of up to an aggregate of $67.5 million for all products and indications. Pieris also agreed to pay Enumeral royalties within a range in the low to lower-middle single digits as a percentage of net sales depending on the amount of net sales in the applicable years. In the event that Pieris is required to pay a license fee or royalty to any third party related to the licensed products, the royalty payment due to Enumeral shall be reduced by the amount of such third party fees or payments, up to 50% of the royalty payment for each calendar year due to Enumeral. Under the Agreement, Pieris has been requested an option for twelve months after the date of the Agreement to license from Enumeral one of a specified set of antibodies owned by Enumeral for use in developing such fusion Anticalin proteins for use in the oncology area. If Pieris licenses an additional antibody pursuant to the option described above, Pieris must pay to Enumeral an additional undisclosed upfront payment, and any resulting fusion protein products will be subject to additional royalties and development and sales milestones in the same amounts applicable to the fusion proteins linking PD-1 and Anticalins under the initial license. The term of the Agreement ends upon the expiration of the last to expire patent covered under the license. The Agreement may be terminated by Pieris on 30 days’ notice and by Enumeral upon 60 days’ notice of a material breach by Pieris (or 30 days with respect to omitted portions marked a breach of payment obligations by Pieris), provided that Pieris has not cured such breach and dispute resolution procedures specified in the Agreement have been followed. The Agreement will also automatically terminate if Pieris elects to not make the maintenance fee payment described above. The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the Agreement, which Pieris intends to file as an exhibit to its Quarterly Report on Form 10-Q for the quarter ended March 31, 2016. Portions of the exhibit, indicated by the xxxx “***”. Exhibit 1.195 [***] CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been ],” were omitted and have been filed separately with the Securities and Exchange Commission. Confidential Commission pursuant to the Registrant’s application requesting confidential treatment has been requested with respect pursuant to omitted portions marked “***”. Exhibit 6.1 Listed Compounds [***] CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been omitted and filed separately with Rule 24b-2 of the Securities and Exchange Commission. Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 6.3(a) [***] Research Plan [***] CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 6.10(b) [***] [4 pages omitted]Act of 1934, as amended.

CONFIDENTIAL TREATMENT REQUESTED. Certain information Exhibit A Patent Rights as of the Effective Date The subject matter that pertains to the First Antibody in this document has been the claims (but not, for example, subject matter that would apply to a different antibody even if contained in the same claim) of the following patent applications: Patent Application No. Filing Date [***] Portions of the exhibit, indicated by the xxxx “[***],” were omitted and have been filed separately with the Securities and Exchange CommissionCommission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with respect to omitted portions marked “***”. CONFIDENTIAL TREATMENT REQUESTED Exhibit 1.168 Takeda Patents Licensed B First Antibody Description [***] Patent Patent / Publication Priority / Application Inventor(s) / Assignee(s) Title / Claims Status Portions of the exhibit, indicated by the xxxx “[***] [***] [***] [***] [***] CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been ],” were omitted and have been filed separately with the Securities and Exchange CommissionCommission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested CONFIDENTIAL TREATMENT REQUESTED Exhibit C Subsequent Antibody Descriptions [As completed with respect to omitted portions marked “***”. Exhibit 1.188 Ultragenyx Patents Ultragenyx the Definitive Agreement:] Enumeral antibodies against [***] Patents and [***] Ultragenyx ], including humanized or chimeric sequences and other Know-How generated through the Option Exercise Date, to be described with specificity, in the event that one or both Subsequent Antibody Options are exercised. Portions of the exhibit, indicated by the xxxx “[***] Patents [***] [3 pages omitted] CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been ],” were omitted and have been filed separately with the Securities and Exchange CommissionCommission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential treatment CONFIDENTIAL TREATMENT REQUESTED Exhibit D Pieris and Enumeral Form 8-K Filings Pieris Form 8-K Disclosure: On April 18, 2016, Pieris Pharmaceuticals, Inc. (the “Company”) and Pieris Pharmaceuticals GmbH, a wholly-owned subsidiary of the Company (together with the Company, “Pieris”), entered into a license and transfer agreement (the “Agreement”) with Enumeral Biomedical Holdings, Inc. (“Enumeral”), pursuant to which Pieris acquired a non-exclusive (except in the exclusive field described below) worldwide license to use specified patent rights and know-how owned by Enumeral to research, develop and market fusion proteins consisting of PD-1 antibodies linked to one or more Anticalin proteins for use in the oncology area. Enumeral also agreed not to practice or assist third parties in practicing in the exclusive field, consisting of licensed antibodies fused to Anticalin proteins in the oncology area. Under the Agreement, Pieris agreed to pay Enumeral an upfront license fee of $250,000 and, on May 31, 2016, a $750,000 maintenance fee. Under the initial license, Pieris also agreed to pay to Enumeral development milestones of up to an aggregate of $37.8 million for all products and indications and sales milestones of up to an aggregate of $67.5 million for all products and indications. Pieris also agreed to pay Enumeral royalties within a range in the low to lower-middle single digits as a percentage of net sales depending on the amount of net sales in the applicable years. In the event that Pieris is required to pay a license fee or royalty to any third party related to the licensed products, the royalty payment due to Enumeral shall be reduced by the amount of such third party fees or payments, up to 50% of the royalty payment for each calendar year due to Enumeral. Under the Agreement, Pieris has been requested an option for twelve months after the date of the Agreement to license from Enumeral one of a specified set of antibodies owned by Enumeral for use in developing such fusion Anticalin proteins for use in the oncology area. If Pieris licenses an additional antibody pursuant to the option described above, Pieris must pay to Enumeral an additional undisclosed upfront payment, and any resulting fusion protein products will be subject to additional royalties and development and sales milestones in the same amounts applicable to the fusion proteins linking PD-1 and Anticalins under the initial license. The term of the Agreement ends upon the expiration of the last to expire patent covered under the license. The Agreement may be terminated by Pieris on 30 days’ notice and by Enumeral upon 60 days’ notice of a material breach by Pieris (or 30 days with respect to omitted portions marked a breach of payment obligations by Pieris), provided that Pieris has not cured such breach and dispute resolution procedures specified in the Agreement have been followed. The Agreement will also automatically terminate if Pieris elects to not make the maintenance fee payment described above. Portions of the exhibit, indicated by the xxxx “***”. Exhibit 1.195 [***] CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been ],” were omitted and have been filed separately with the Securities and Exchange Commission. Confidential Commission pursuant to the Registrant’s application requesting confidential treatment has been requested with respect pursuant to omitted portions marked “***”. Exhibit 6.1 Listed Compounds [***] CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been omitted and filed separately with Rule 24b-2 of the Securities and Exchange Commission. Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 6.3(a) [***] Research Plan [***] CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 6.10(b) [***] [4 pages omitted]Act of 1934, as amended.

CONFIDENTIAL TREATMENT REQUESTED. Certain information THE REGISTRANT HAS REQUESTED CONFIDENTIAL TREATMENT FOR CERTAIN PORTIONS OF THIS AGREEMENT. THOSE PORTIONS HAVE BEEN OMITTED FROM THIS COPY OF THE AGREEMENT AT THE PLACES INDICATED BY (XXXX); AND HAVE BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION XXXXXX Confidential Treatment Requested THE REGISTRANT HAS REQUESTED CONFIDENTIAL TREATMENT FOR CERTAIN PORTIONS OF THIS AGREEMENT. THOSE PORTIONS HAVE BEEN OMITTED FROM THIS COPY OF THE AGREEMENT AT THE PLACES INDICATED BY (XXXX); AND HAVE BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION Attachment 2 Method of Manufacture for Drug Substance Drug Substance will be Manufactured according to Batch records written by CBSI and approved by Centocor. Other Production documents required for Manufacture include but are not limited to those set forth in this document has been omitted XXXXXX Confidential Treatment Requested THE REGISTRANT HAS REQUESTED CONFIDENTIAL TREATMENT FOR CERTAIN PORTIONS OF THIS AGREEMENT. THOSE PORTIONS HAVE BEEN OMITTED FROM THIS COPY OF THE AGREEMENT AT THE PLACES INDICATED BY (XXXX); AND HAVE BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION Attachment 3 Authorized Representatives of the Parties The following represents the list of people allowed to approve changes to these Quality Requirements ("Authorized Representatives"). Any change must be signed by at least one Centocor Authorized Quality Representative and filed separately with the Securities and Exchange Commissionone Centocor Authorized Operation Representative. CENTOCOR -------- Centocor Quality Representatives -------------------------------- XXXXXX XXXXXX XXXXXX Centocor Authorized Representatives ----------------------------------- XXXXXX XXXXXX XXXXXX Centocor Operations Representatives ----------------------------------- XXXXXX XXXXXX XXXXXX XXXXXX XXXXXX XXXXXX Confidential treatment has been requested with respect to omitted portions marked “Treatment Requested THE REGISTRANT HAS REQUESTED CONFIDENTIAL TREATMENT FOR CERTAIN PORTIONS OF THIS AGREEMENT. THOSE PORTIONS HAVE BEEN OMITTED FROM THIS COPY OF THE AGREEMENT AT THE PLACES INDICATED BY (XXXX); AND HAVE BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION CBSI ---- CBSI Quality Representatives ---------------------------- XXXXXX XXXXXX CBSI Authorized Representatives ------------------------------- XXXXXX XXXXXX CBSI Operation Representatives ------------------------------ XXXXXX XXXXXX XXXXXX XXXXXX XXXXXX XXXXXX Confidential Treatment Requested THE REGISTRANT HAS REQUESTED CONFIDENTIAL TREATMENT FOR CERTAIN PORTIONS OF THIS AGREEMENT. THOSE PORTIONS HAVE BEEN OMITTED FROM THIS COPY OF THE AGREEMENT AT THE PLACES INDICATED BY (XXXX); AND HAVE BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION XXXXXX Confidential Treatment Requested THE REGISTRANT HAS REQUESTED CONFIDENTIAL TREATMENT FOR CERTAIN PORTIONS OF THIS AGREEMENT. THOSE PORTIONS HAVE BEEN OMITTED FROM THIS COPY OF THE AGREEMENT AT THE PLACES INDICATED BY (XXXX); AND HAVE BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION XXXXXX Confidential Treatment Requested THE REGISTRANT HAS REQUESTED CONFIDENTIAL TREATMENT FOR CERTAIN PORTIONS OF THIS AGREEMENT. THOSE PORTIONS HAVE BEEN OMITTED FROM THIS COPY OF THE AGREEMENT AT THE PLACES INDICATED BY (XXXX); AND HAVE BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION ***”CONFIDENTIAL *** XXXXXX Confidential Treatment Requested THE REGISTRANT HAS REQUESTED CONFIDENTIAL TREATMENT FOR CERTAIN PORTIONS OF THIS AGREEMENT. Exhibit 1.168 Takeda Patents Licensed [THOSE PORTIONS HAVE BEEN OMITTED FROM THIS COPY OF THE AGREEMENT AT THE PLACES INDICATED BY (XXXX); AND HAVE BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION ***] Patent Patent / Publication Priority / Application Inventor(s) / Assignee(s) Title / Claims Status [CONFIDENTIAL *** XXXXXX Confidential Treatment Requested THE REGISTRANT HAS REQUESTED CONFIDENTIAL TREATMENT FOR CERTAIN PORTIONS OF THIS AGREEMENT. THOSE PORTIONS HAVE BEEN OMITTED FROM THIS COPY OF THE AGREEMENT AT THE PLACES INDICATED BY (XXXX); AND HAVE BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION ***CONFIDENTIAL*** XXXXXX [signature] [--------------- Signature ***] [FOR INFORMATIONAL USE ONLY***] [***] [***] * Confidential Treatment Requested THE REGISTRANT HAS REQUESTED CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been omitted and filed separately with the Securities and Exchange CommissionFOR CERTAIN PORTIONS OF THIS AGREEMENT. Confidential treatment has been requested with respect THOSE PORTIONS HAVE BEEN OMITTED FROM THIS COPY OF THE AGREEMENT AT THE PLACES INDICATED BY (XXXX); AND HAVE BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION Attachment 6 Storage Conditions for Drug Substance According to omitted portions marked “***”. Exhibit 1.188 Ultragenyx Patents Ultragenyx [***] Patents [***] Ultragenyx [***] Patents [***] [3 pages omitted] CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 1.195 [***] CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 6.1 Listed Compounds [***] CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 6.3(a) [***] Research Plan [***] CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 6.10(b) [***] [4 pages omitted]approved Centocor procedures.

CONFIDENTIAL TREATMENT REQUESTED. Certain information in this document has been Confidential Exhibit 1.20: Arising Patents To be updated from time to time. 134 Portions of the exhibit, indicated by the xxxx “[***],” were omitted and have been filed separately with the Securities and Exchange CommissionCommission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. CONFIDENTIAL TREATMENT REQUESTED Confidential treatment has been requested with respect Exhibit 1.23: Patents within the AstraZeneca Background Improvement IP To be updated from time to omitted portions marked time. 135 Portions of the exhibit, indicated by the xxxx “***”. Exhibit 1.168 Takeda Patents Licensed [***] Patent Patent / Publication Priority / Application Inventor(s) / Assignee(s) Title / Claims Status [***] [***] [***] [***] [***] CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been ],” were omitted and have been filed separately with the Securities and Exchange CommissionCommission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. CONFIDENTIAL TREATMENT REQUESTED Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 1.188 Ultragenyx Patents Ultragenyx 1.40: Technical Candidate Drug Criteria [***, 5 pages] Patents 136 Portions of the exhibit, indicated by the xxxx “[***] Ultragenyx [***] Patents [***] [3 pages omitted] CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been ],” were omitted and have been filed separately with the Securities and Exchange CommissionCommission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. CONFIDENTIAL TREATMENT REQUESTED Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 1.195 1.43: Clinical Failure Criteria [***, 1 page] CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been 137 Portions of the exhibit, indicated by the xxxx “[***],” were omitted and have been filed separately with the Securities and Exchange CommissionCommission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 6.1 Listed Compounds [***] CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 6.3(a) [***] Research Plan [***] CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 6.10(b) [***] [4 pages omitted]Confidential

CONFIDENTIAL TREATMENT REQUESTED. Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 1.168 Takeda Patents Licensed 1.1-D [***] Patent Patent / Publication Priority / Application Inventor(s) / Assignee(s) Title / Claims Status [***] [***] [***] [***] [***] * CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. Execution Version CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 1.188 Ultragenyx Patents Ultragenyx 1.1-E [***] Patents [***] Ultragenyx [***] Patents [***] [3 pages omitted] * CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. Execution Version CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 1.195 1.1-F [***] * CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. Execution Version CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 6.1 Listed Compounds 2.1.4 [***] * CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. Execution Version CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 6.3(a) [***] Research Plan [***] * CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. Execution Version CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 6.10(b) 7.1.6 [**] * CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. Execution Version CONFIDENTIAL TREATMENT REQUESTED Exhibit 7.1.10 [*] * CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. Execution Version CONFIDENTIAL TREATMENT REQUESTED Disclosure Schedule [4 pages omitted]*] * CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. Execution Version

CONFIDENTIAL TREATMENT REQUESTED. Certain information in BY ASSEMBLY BIOSCIENCES, INC. IN WITNESS WHEREOF this document Agreement has been signed by the duly authorized representatives of the Parties as of the Execution Date. SIGNED for and by behalf of ASSEMBLY BIOSCIENCES, INC. /s/ Dxxxx X. Small Dxxxx X. Small, President & CEO Print Name and Title SIGNED for and by behalf of ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED /s/ Txx Xxxxx Txx Xxxxx, Director Print Name and Title [Signature Page to Research, Development, Collaboration and License Agreement] [* * *] The confidential content of this Exhibit 10.1 has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions marked “***”portions. CONFIDENTIAL TREATMENT REQUESTED BY ASSEMBLY BIOSCIENCES, INC. Exhibit 1.168 Takeda Patents Licensed A Irritable bowel syndrome – constipation, diarrhea and mixed (IBS-c, IBS-d and IBS-m) Ulcerative colitis (UC) Crohn’s disease [***] Patent Patent / Publication Priority / Application Inventor(s) / Assignee(s) Title / Claims Status [*** * *] [*** * *] [***] [***] [***] CONFIDENTIAL TREATMENT REQUESTED Certain information in The confidential content of this document Exhibit 10.1 has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions marked “***”portions. Exhibit 1.188 Ultragenyx Patents Ultragenyx CONFIDENTIAL TREATMENT REQUESTED BY ASSEMBLY BIOSCIENCES, INC. Schedule 1.1 201 Compound Candidate (Initial Indication - ulcerative colitis) 201 Compound Candidate is under development. [*** * *] Patents for 201 Compound Candidate (Initial Indication - ulcerative colitis) [***] Ultragenyx [***] Patents [*** * *] [3 pages omitted* * *] CONFIDENTIAL TREATMENT REQUESTED Certain information in The confidential content of this document Exhibit 10.1 has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions marked “***”portions. Exhibit 1.195 [***] CONFIDENTIAL TREATMENT REQUESTED Certain information in BY ASSEMBLY BIOSCIENCES, INC. Schedule 1.2 301 Compound Candidate (Initial Indication - Crohn’s disease) 301 Compound Candidate is under development. [* * *] for 301 Compound Candidate (Initial Indication - Crohn’s disease) [* * *] [* * *] The confidential content of this document Exhibit 10.1 has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions marked “***”portions. Exhibit 6.1 Listed Compounds [***] CONFIDENTIAL TREATMENT REQUESTED Certain information in BY ASSEMBLY BIOSCIENCES, INC. Schedule 1.103 Knowledge Knowledge – Assembly [* * *] Knowledge – Allergan [* * *] [* * *] The confidential content of this document Exhibit 10.1 has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions marked “***”portions. Exhibit 6.3(a) [***] Research Plan [***] CONFIDENTIAL TREATMENT REQUESTED Certain information in BY ASSEMBLY BIOSCIENCES, INC. Schedule 1.108 Licensed Compound Patents [* * *] [* * *] The confidential content of this document Exhibit 10.1 has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions marked “portions. CONFIDENTIAL TREATMENT REQUESTED BY ASSEMBLY BIOSCIENCES, INC. [* * ***”. Exhibit 6.10(b) ] Patent/ Application Number Patent Filing Date Title Remarks [*** * *] [4 pages omitted]* * *] [* * *] [* * *] [* * *] [* * *] [* * *] [* * *] [* * *] [* * *] [* * *] [* * *] [* * *] The confidential content of this Exhibit 10.1 has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. CONFIDENTIAL TREATMENT REQUESTED BY ASSEMBLY BIOSCIENCES, INC. Schedule 1.153 R&D Plan [* * *] RESEARCH AND DEVELOPMENT PLAN OUTLINE [* * *] [* * *] The confidential content of this Exhibit 10.1 has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. CONFIDENTIAL TREATMENT REQUESTED BY ASSEMBLY BIOSCIENCES, INC. Schedule 8.5.1(c) Press Releases NEWS RELEASE CONTACTS: ALLERGAN ASSEMBLY INVESTORS: INVESTORS: Lxxx XxXxxxxxxxx Lxxxxx Xxxxxx (000) 000-0000 (000) 000-0000 MEDIA: MEDIA: Mxxx Xxxxxx Bxxxxxx Xxxxxxxx (000) 000-0000 (000) 000-0000 Allergan Enters Into Licensing Agreement with Assembly Biosciences to Obtain Worldwide Rights to Microbiome Gastrointestinal Development Programs — Expands Allergan’s Innovative GI Pipeline with ABI-M201 and ABI-M301, Preclinical Compounds Targeting Ulcerative Colitis and Crohn’s Disease, as well as Future Compounds for Irritable Bowel Syndrome — DUBLIN, IRELAND and INDIANAPOLIS, INDIANA (USA) – January 9, 2017 – Allergan plc (NYSE: AGN) and Assembly Biosciences, Inc. (NASDAQ: ASMB) today announced that Allergan has entered into a research, development, collaboration and license agreement for the worldwide rights to Assembly’s microbiome gastrointestinal (GI) development programs. The agreement provides Allergan with worldwide rights to preclinical compounds ABI-M201 and ABI-M301, targeting ulcerative colitis (UC) and Crohn’s disease (CD), as well as two additional compounds to be identified by Assembly for Irritable Bowel Syndromes (IBS); with Diarrhea (IBS-D), with Constipation (IBS-C) or Mixed (IBS-M). Under the terms of the agreement, Allergan will make an upfront payment to Assembly of $50 million for the exclusive, worldwide rights to develop and commercialize the UC, CD and IBS compounds. Additionally, Assembly will be entitled to receive success-based development and commercial milestone payments. Assembly is also eligible to receive tiered royalties based on net sales. Allergan and Assembly will generally share development costs through proof-of-concept (POC) studies, and Allergan will assume all post-POC development costs. [* * *] The confidential content of this Exhibit 10.1 has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

CONFIDENTIAL TREATMENT REQUESTED. Certain information in portions of this document have been omitted pursuant to a request for confidential treatment and, where applicable, have been marked with an asterisk (“[*****]”) to denote where omissions have been made. The confidential material has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to omitted portions marked “***”PROCEEDING AND, SOLELY FOR THE PURPOSES OF ENFORCING THIS AGREEMENT, OWNER AND MANAGER EACH IRREVOCABLY SUBMITS TO THE JURISDICTION OF ANY SUCH COURT IN ANY SUCH SUIT, ACTION OR PROCEEDING. Exhibit 1.168 Takeda Patents Licensed [***] Patent Patent / Publication Priority / Application Inventor(s) / Assignee(s) Title / Claims Status [***] [***] [***] [***] [***] CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been omitted and filed separately with the Securities and Exchange CommissionOWNER AND MANAGER EACH IRREVOCABLY APPOINTS AND DESIGNATES ICAHN ASSOCIATES CORP., HAVING AN ADDRESS AT 000 XXXXX XXXXXX, XXX XXXX, XXX XXXX 00000, ATTENTION: LEGAL DEPARTMENT, AS ITS TRUE AND LAWFUL ATTORNEY-IN-FACT AND DULY AUTHORIZED AGENT FOR THE LIMITED PURPOSE OF ACCEPTING SERVICING OF LEGAL PROCESS, AND OWNER AND MANAGER EACH AGREES THAT SERVICE OF PROCESS UPON SUCH PARTY SHALL CONSTITUTE PERSONAL SERVICE OF SUCH PROCESS ON SUCH PERSON. Confidential treatment has been requested with respect to omitted portions marked “***”OWNER AND MANAGER EACH SHALL MAINTAIN THE DESIGNATION AND APPOINTMENT OF SUCH AUTHORIZED AGENT UNTIL ALL AMOUNTS PAYABLE UNDER THIS AGREEMENT SHALL HAVE BEEN PAID IN FULL. Exhibit 1.188 Ultragenyx Patents Ultragenyx [***] Patents [***] Ultragenyx [***] Patents [***] [3 pages omitted] CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 1.195 [***] CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 6.1 Listed Compounds [***] CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 6.3(a) [***] Research Plan [***] CONFIDENTIAL TREATMENT REQUESTED Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to omitted portions marked “***”. Exhibit 6.10(b) [***] [4 pages omitted]IF SUCH AGENT SHALL CEASE TO SO ACT, OWNER OR MANAGER, AS THE CASE MAY BE, SHALL IMMEDIATELY DESIGNATE AND APPOINT ANOTHER SUCH AGENT SATISFACTORY TO THE OTHER PARTY HERETO AND SHALL PROMPTLY DELIVER TO THE OTHER PARTY HERETO EVIDENCE IN WRITING OF SUCH OTHER AGENT’S ACCEPTANCE OF SUCH APPOINTMENT.